Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -156.77% is 41% below its 5-year average of -111.47%, near the high end of its 5-year range (-488.53%–-39.43%).
As of the fiscal period ended Friday, July 31, 2026. 14.15% above its 12-month average of -182.61%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2027 (2026-07-31): -156.77%.
RETURN ON EQUITY (ROE)
-156.77%
RETURN ON EQUITY (ROE) AVG TTM
-182.61%
RETURN ON EQUITY (ROE) AVG 3Y
-160.37%
RETURN ON EQUITY (ROE) AVG 5Y
-111.47%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+14.15%
CURRENT VS 3Y AVG
+2.25%
CURRENT VS 5Y AVG
-40.63%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-273.17%
vs the sector median at left
Alzamend Neuro Inc
Market Cap
$5.21M
Return on Equity (ROE)
-156.77%
TTM Avg
-182.61%
3Y Avg
-160.37%
5Y Avg
-111.47%
Market Cap
$5.21M
Return on Equity (ROE)
-248.66%
TTM Avg
-110.63%
3Y Avg
-33.84%
5Y Avg
-33.84%
Market Cap
$5.22M
Return on Equity (ROE)
-156.94%
TTM Avg
-121.17%
3Y Avg
-95.34%
5Y Avg
-84.55%
Market Cap
$5.24M
Return on Equity (ROE)
-225.57%
TTM Avg
-289.16%
3Y Avg
-245.03%
5Y Avg
-192.04%
Market Cap
$5.12M
Return on Equity (ROE)
N/A
TTM Avg
383.38%
3Y Avg
131.31%
5Y Avg
101.98%
Market Cap
$5.31M
Return on Equity (ROE)
-154.08%
TTM Avg
-205.06%
3Y Avg
-23.78%
5Y Avg
-114.15%
Market Cap
$5.32M
Return on Equity (ROE)
-42.05%
TTM Avg
-32.76%
3Y Avg
-25.11%
5Y Avg
-45.26%
Market Cap
$5.35M
Return on Equity (ROE)
-163.18%
TTM Avg
-235.11%
3Y Avg
-195.15%
5Y Avg
-161.13%
Market Cap
$4.97M
Return on Equity (ROE)
-4165.92%
TTM Avg
61.14%
3Y Avg
-23.12%
5Y Avg
-18.15%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alzamend Neuro Inc (ALZN) | $5.21M | -156.77% | -182.61% | -160.37% | -111.47% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.21M | -248.66% | -110.63% | -33.84% | -33.84% |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | -156.94% | -121.17% | -95.34% | -84.55% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | -225.57% | -289.16% | -245.03% | -192.04% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | N/A | 383.38% | 131.31% | 101.98% |
| Soligenix, Inc. (SNGX)vs › | $5.31M | -154.08% | -205.06% | -23.78% | -114.15% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | -42.05% | -32.76% | -25.11% | -45.26% |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | -163.18% | -235.11% | -195.15% | -161.13% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | -4165.92% | 61.14% | -23.12% | -18.15% |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.86M | -40.76% | -51.09% | -48.10% | -52.04% |
ROE
-156.8%
ROA
-106.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-07-31 | -156.77% |
| 2026-01-31 | -322.36% |
| 2025-10-31 | -134.48% |
| 2025-07-31 | -116.84% |
| 2025-04-30 | -113.78% |
| 2025-01-31 | -122.53% |
| 2024-10-31 | -155.87% |
| 2023-04-30 | -488.53% |
| 2023-01-31 | -263.54% |
| 2022-10-31 | -143.27% |
| 2022-07-31 | -116.97% |
| 2022-04-30 | -92.59% |
| 2022-01-31 | -81.50% |
| 2021-10-31 | -63.69% |
| 2021-07-31 | -39.43% |
| 2021-04-30 | -250.71% |
| 2020-04-30 | -536.66% |
| 2020-01-31 | -183.64% |
| 2019-10-31 | -167.13% |
| 2019-07-31 | -193.55% |
| 2018-10-31 | -247.43% |
| 2018-07-31 | -154.85% |
| 2018-04-30 | -40.18% |
| 2018-01-31 | -43.30% |
